BioViva is building a gene-therapy platform using a cytomegalovirus (CMV) that can carry a genetic payload three times larger than the AAV. The company hopes to expand this to at least 10 times ...
According to TSN insider Pierre LeBrun, reporting the news on Friday, the Leafs have set a maximum offer of $13 million per season in average annual value (AAV ... 10.9 million cap hit this ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈